arrow
K

Kaïdre Bendjama

nec bio b.v.
H指数:11
被引数:565

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial

基于病毒载体的个体化新抗原疫苗作为头颈部鳞状细胞癌切除术后辅助治疗:一项随机I期临床试验

2026-08-170
OAAI
Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers
2023-09-016
PRE
Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer
2023-04-141
PRE
Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer

在TMB低非小细胞肺癌中靶向肿瘤突变组进行个性化疫苗接种

2022-03-3113
OAAI
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

治疗性疫苗TG1050在慢性乙型肝炎患者中的安全性和免疫原性: 1b期安慰剂对照试验

2019-10-0468
OAAI
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-Gal and MVA-MUC1 (TG4010) in a murine tumor model

基于MVA的疫苗和PD-1/PD-L1-blocking抗体的序贯给药对肿瘤生长和存活带来可测量的益处: mva-gal和MVA-MUC1 (TG4010) 在小鼠肿瘤模型中的临床前研究

2017-10-1824
OAAI
A generic operational strategy to qualify translational safety biomarkers
2011-07-0158
PREAI